8-KEarnings & ResultsExhibits & Filings

Merck & Co., Inc. 8-K Report, Financial Results (Feb 3, 2026)

Filed February 3, 2026For Securities:MRK

Summary

Merck & Co., Inc. (MRK) has filed an 8-K report on February 3, 2026, to announce its financial results for the fourth quarter and full year ended 2025. The filing incorporates by reference a press release (Exhibit 99.1) and supplemental information (Exhibit 99.2) detailing these results. While the specific financial figures are not directly presented in the 8-K text, investors are directed to the attached exhibits for a comprehensive overview of the company's performance, including key operational and financial metrics. This report serves as the primary disclosure mechanism for Merck's 2025 year-end and Q4 earnings. Investors should review Exhibits 99.1 and 99.2 for detailed insights into revenue, profitability, segment performance, and any forward-looking guidance or commentary provided by management. The information furnished is critical for understanding the company's financial health and its trajectory heading into the new fiscal year.

Key Highlights

  • 1Merck & Co., Inc. (MRK) released its Q4 and full-year 2025 financial results on February 3, 2026.
  • 2The 8-K filing incorporates by reference a press release (Exhibit 99.1) with detailed earnings information.
  • 3Supplemental financial information not included in the press release is provided as Exhibit 99.2.
  • 4Investors must consult the attached exhibits for specific financial performance data and management commentary.
  • 5The filing pertains to the financial results of the fiscal year ending in 2025.
  • 6This report is a key update on Merck's financial condition and results of operations.

Frequently Asked Questions

The actual financial results are detailed in the press release (Exhibit 99.1) and supplemental information (Exhibit 99.2) incorporated by reference in this 8-K filing. Investors should refer to these exhibits for specific revenue, profit, and other financial metrics.

This 8-K filing is significant as it officially announces and provides access to Merck's most recent quarterly and annual financial performance, offering critical data for investors to assess the company's financial health, operational success, and potential future performance.

While the 8-K text itself does not contain forward-looking statements, the incorporated press release (Exhibit 99.1) and supplemental information (Exhibit 99.2) typically include management's commentary, outlook, and potentially forward-looking guidance. Investors should review these exhibits for such information.

The financial results reported in this 8-K filing are for the fourth quarter and the full year ended 2025.